VR Adviser LLC lowered its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,220,130 shares of the company's stock after selling 175,476 shares during the period. Pharvaris accounts for 4.2% of VR Adviser LLC's investment portfolio, making the stock its 8th biggest position. VR Adviser LLC owned about 6.16% of Pharvaris worth $61,730,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in PHVS. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Pharvaris in the fourth quarter valued at $64,000. Barclays PLC acquired a new position in Pharvaris in the third quarter valued at $106,000. KLP Kapitalforvaltning AS acquired a new position in Pharvaris in the fourth quarter valued at $111,000. Finally, Point72 Asset Management L.P. acquired a new position in Pharvaris in the fourth quarter valued at $152,000.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Cantor Fitzgerald reduced their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. JMP Securities lifted their target price on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Get Our Latest Research Report on PHVS
Pharvaris Trading Down 2.4%
Shares of PHVS traded down $0.40 during midday trading on Friday, reaching $15.99. 16,327 shares of the company were exchanged, compared to its average volume of 72,866. The stock has a 50-day moving average price of $15.39 and a 200-day moving average price of $17.36. The company has a market cap of $836.12 million, a price-to-earnings ratio of -5.71 and a beta of -2.85. Pharvaris has a 1-year low of $11.51 and a 1-year high of $25.50.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). Equities research analysts anticipate that Pharvaris will post -2.71 earnings per share for the current year.
Pharvaris Company Profile
(
Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
